Exploring the Potential of Sulfonamide-Dihydropyridine Hybrids as Multitargeted Ligands for Alzheimer's Disease Treatment

Int J Mol Sci. 2023 Jun 4;24(11):9742. doi: 10.3390/ijms24119742.

Abstract

Alzheimer's disease (AD) is a multifactorial neurodegenerative disease that has a heavy social and economic impact on all societies and for which there is still no cure. Multitarget-directed ligands (MTDLs) seem to be a promising therapeutic strategy for finding an effective treatment for this disease. For this purpose, new MTDLs were designed and synthesized in three steps by simple and cost-efficient procedures targeting calcium channel blockade, cholinesterase inhibition, and antioxidant activity. The biological and physicochemical results collected in this study allowed us the identification two sulfonamide-dihydropyridine hybrids showing simultaneous cholinesterase inhibition, calcium channel blockade, antioxidant capacity and Nrf2-ARE activating effect, that deserve to be further investigated for AD therapy.

Keywords: Hantzsch reaction; Nrf2; calcium channel antagonism; cholinesterase inhibition; multitarget directed ligands.

MeSH terms

  • Acetylcholinesterase / metabolism
  • Alzheimer Disease* / drug therapy
  • Calcium Channels
  • Cholinesterase Inhibitors / pharmacology
  • Cholinesterase Inhibitors / therapeutic use
  • Cholinesterases / metabolism
  • Dihydropyridines* / pharmacology
  • Dihydropyridines* / therapeutic use
  • Humans
  • Ligands
  • Neurodegenerative Diseases* / drug therapy

Substances

  • Cholinesterase Inhibitors
  • Ligands
  • Dihydropyridines
  • Calcium Channels
  • Cholinesterases
  • Acetylcholinesterase

Grants and funding

This work was supported by the Regional Council of Franche-Comté (2022Y-13659 and 13660 Accurate Project).